Competing interests
NSR, Cancer
ONCOLOGY, CANCER, MYELOMA, EMD
Y.L. received institutional grants and consulting fees from Bristol Myers Squibb, Kite-Gilead and Janssen; institutional grants only from 2Seventy Bio, Merck and Takeda; institutional consulting fees only from Novartis, CellMedica and Legend Biotech; and participated in a data safety monitoring or advisory board for Pfizer and Sorrento. NSR received consulting fees from Bristol Myers Squibb and research funding from 2Seventy Bio. J.G.B. reports institutional support from Bristol Myers Squibb during the conduct of the study; received institutional grants and consulting fees from bluebird bio, Celgene, Janssen, Takeda and CRISPR Therapeutics; received institutional grants only from 2Seventy Bio, Acetylon, CARsgen, Fate Therapeutics, GlaxoSmithKline, Incyte, Karyopharm, Novartis, Sanofi, Teva, AbbVie, Amgen, C4 Therapeutics, Cartesian, Celularity, EMD Sorono, Genentech, Icnos Sciences, Lilly, Poseida and Zentalis; and received institutional consulting fees only from Legend Biotech, Bristol Myers Squibb, Kite Pharma and Secura Bio. D.S.S. reports nonfinancial support from Bristol Myers Squibb during the conduct of the study and received consulting and personal fees from Bristol Myers Squibb for participation in advisory boards and speaker bureaus. S.J. received consulting fees from Bristol Myers Squibb, Janssen, Karyopharm, Legend Biotech, Sanofi and Takeda; participated in a Data Monitoring Committee; and has a leadership or fiduciary role at the International Myeloma Society, Society of Hematologic Oncology and American Society of Hematology. D.M. was an employee of Mount Sinai Medical Center, New York, at the time the work was conducted and received consulting/advisory fees from Roivant, Takeda, Janssen Oncology, Celgene, Legend Biotech, GlaxoSmithKline and Foundation Medicine, but is now an employee of Janssen Oncology with stock and other ownership interests. M.L. reports consultant fees/grants from Allogene, bluebird bio, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen Biotech, Karyopharm Therapeutics, Oncopeptides, Sanofi and Takeda. J.R. received grants from Celgene and Bristol Myers Squibb, consulting fees from Parexel, Imaging Endpoint, Bioclinica and Attivare Therapeutics, and participated in a data safety monitoring board for Karyopharm and advisory boards for Amgen, Bristol Myers Squibb, Merck, Kite Pharma, Partner TX, Celgene and Dava Oncology. M.V.M. received research funding from Kite Pharma and Novartis; royalties from Novartis; consulting fees from Adaptimmune, Agenus, Allogene, Arcellx, Astellas, AstraZeneca, Atara, Bayer, Bristol Myers Squibb, Cabaletta Bio, Cellectis, CRISPR Therapeutics, Genocea, In8bio, Intellia, GlaxoSmithKline, Kite Pharma, Micromedicine/BendBio, Neximmune, Novartis, Oncternal, Sanofi, TCR2, Tmunity and WindMIL; payment for expert testimony from Australia FPA patent attorneys; participated in a data safety monitoring or advisory board for Adaptimmune, GlaxoSmithKline and Cabaletta Bio; has multiple patents not related to this work; holds stock or has stock options in 2Seventy Bio, Century Therapeutics, Genocea, Neximmune, Oncternal and TCR2; and is on the board of directors for 2Seventy Bio since the completion of this work. M.M., F.P., A.Y. and O.F. report employment at 2Seventy Bio/bluebird bio. F.P. and O.F. also hold stocks in 2Seventy Bio/bluebird bio. A.C., N.M., T.B.C., J.F. and J.R. report employment at Bristol Myers Squibb. Z.Y. and K.H. are former employees of Bristol Myers Squibb. Z.Y. is currently employed at Ascentage Pharma. Z.Y., N.M., T.B.C., J.F., J.R. and K.H. also hold stocks in Bristol Myers Squibb. K.H. also has a leadership or fiduciary role at Mersana Therapeutics, Graphite Bio and the Society for Immunotherapy of Cancer. J.R. also reports holding stock in Adaptive Biotechnologies. N.C.M. reports stock and other ownership interests from OncoPep, C4 Therapeutics and Raqia, and consulting fees from AbbVie, Adaptive Biotechnologies, Amgen, BeiGene, Bristol Myers Squibb, Bristol Myers Squibb/Celgene, Janssen, OncoPep, Karyopharm Therapeutics, Legend Biotech, Novartis, RaqiaPatents, Sebia and Takeda; he is also the recipient of grants from the National Cancer Institute. J.N.K. is the principal investigator of a research agreement between Celgene, Bristol Myers Squibb and the National Cancer Institute that provided funding for this work and the principal investigator of a research agreement between Kite, a Gilead company, and the National Cancer Institute; received CAR T cells for this work from Celgene; has a patent for CARs targeting B-cell maturation agent used in this work for which he receives royalties; and has received royalties from Kite, a Gilead Company, and Kyverna for unrelated work.